Bioinformatics Analysis of Potential Key Genes in Trastuzumab-Resistant Gastric Cancer

Table 3

Overall survival analysis based on the expression of the hub genes.

Gene name	ID	OS (all)		OS (HER2-)		OS (HER2+)
		HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value
ERBB2	210930_s_at	1.37 (1.14-1.65)	0.00088	1.33 (1.06-1.66)	0.013	0.73 (0.55-0.97)	0.027
VIM	201426_s_at	1.29 (1.09-1.53)	0.0031	1.52 (1.21-1.9)	0.00027	1.4 (1.01-1.92)	0.04
EGR1	201694_s_at	0.63 (0.52-0.76)	8.5	0.78 (0.61-1)	0.052	0.6 (0.46-0.79)	0.00023
PSMB8	209040_s_at	0.45 (0.37-0.56)	6.6	0.39 (0.3-0.5)	1.7	0.62 (0.46-0.85)	0.0024
IFI44	214059_at	1.46 (1.22-1.74)	0.000028	1.39 (1.1-1.75)	0.0056	1.67 (1.28-2.19)	0.00015
IFI44L	204439_at	0.85 (0.71-1.03)	0.1	0.75 (0.58-0.98)	0.037	1.59 (1.16-2.19)	0.0037
IFIT2	217502_at	1.26 (1.04-1.53)	0.018	0.84 (0.67-1.05)	0.12	1.7 (1.24-2.33)	0.00075
IFIT3	204747_at	1.14 (0.95-1.36)	0.16	0.75 (0.59-0.95)	0.017	1.54 (1.15-2.07)	0.0037
ISG15	205483_s_at	0.86 (0.71-1.03)	0.094	0.73 (0.56-0.93)	0.012	1.5 (1.1-2.05)	0.01
OAS1	202869_at	1.15 (0.97-1.37)	0.1	0.79 (0.63-0.99)	0.039	1.39 (1.07-1.8)	0.013
OASL	210797_s_at	1.16 (0.98-1.37)	0.09	0.84 (0.67-1.05)	0.12	1.41 (1.04-1.92)	0.028
SAMD9	219691_at	0.73 (0.61-0.88)	0.00065	0.57 (0.44-0.74)	0.00002	1.23 (0.94-1.6)	0.14
BST2	201641_at	0.7 (0.58-0.85)	0.00027	0.55 (0.42-0.7)	1.9	1.28 (0.94-1.73)	0.12
IFI27	202411_at	0.7 (0.59-0.84)	0.000096	0.58 (0.46-0.73)	1.8	0.85 (0.63-1.13)	0.26
IFIT1	203153_at	0.73 (0.61-0.87)	0.00061	0.63 (0.49-0.81)	0.00025	1.23 (0.95-1.6)	0.12
IFITM3	212203x_at	1.09 (0.91-1.29)	0.36	0.89 (0.71-1.12)	0.32	1.27 (0.96-1.69)	0.096
MX1	202086_at	1.27 (1.05-1.54)	0.015	1.15 (0.9-1.47)	0.26	1.32 (0.99-1.76)	0.056
OAS2	204972_at	0.91 (0.77-1.08)	0.3	0.77 (0.61-0.96)	0.021	1.25 (0.93-1.67)	0.13

Abbreviation: OS: overall survival; HER2-: human epidermal growth factor receptor-2 negative; HER2+: human epidermal growth factor receptor-2 positive.